Our Latest Stories
Our Science
January 15, 2025
Achieving R&D Excellence to Shape the Medicines of Tomorrow
Third quarter 2024 results
Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session.
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an innovative global healthcare company.
Our Pipeline
5
Therapeutic areas
78
Compounds in clinical development
27
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
January 13, 2025
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
January 9, 2025
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
December 23, 2024
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
December 19, 2024
Press Release: Jean-Paul Kress to join Sanofi's Board of Directors